DSIP + Epitalon Blend
How this combination works
The community rationale is to pair DSIP, the peptide named for sleep induction, with Epitalon, which is reported to restore nocturnal melatonin secretion and circadian rhythm amplitude in older subjects. The idea is that one acts on sleep itself and the other on the circadian signal that times it. Both evidence bases are thin: DSIP's link to sleep has not been definitively established, and Epitalon's melatonin findings come from small human observational studies and animal work. This rationale is mechanistic inference only.
Combined mechanism
DSIP is a nonapeptide that was isolated in 1977 as a sleep-promoting factor, though its link to sleep has not been definitively established. It modulates GABAergic Cl⁻ flux, crosses the blood-brain barrier through a saturable transport mechanism and is rapidly degraded in blood by aminopeptidases. In human insomnia studies it had a slight arousing effect in the first hour after IV injection, with sleep-promoting effects only in the second hour. Epitalon (Ala-Glu-Asp-Gly) stimulates AANAT and pCREB in pinealocyte culture, increasing melatonin, and restores nocturnal melatonin secretion and circadian rhythm amplitude in elderly humans and old monkeys. Its precise primary receptor remains uncertain. No human pharmacokinetic or pharmacodynamic data exist for the combination.
What each component does
Evidence base for this combination
Safety considerations for this combination
- No combination-specific safety data exist for DSIP + Epitalon. The signals below come from each compound studied on its own. Component approved files
- DSIP shows bell-shaped dose-response curves in animal studies — doses outside the effective range were ineffective or produced different effects — which makes dose-finding in any combination unpredictable. DSIP: PMID: 6548967
- Headaches reported by a few patients during intravenous DSIP treatment for alcohol and opiate withdrawal (107-patient clinical study). Inherited from DSIP (PMID: 6548969)
- Slight arousing/activating effect (rather than sedating) observed in the first hour after intravenous injection in human insomnia studies; sleep-promoting effects only emerged in the second hour. Inherited from DSIP (PMID: 7028502)
- Rapid degradation in blood (release of tryptophan, rate dependent on temperature and species) may contribute to variable and inconsistent in vivo effects. Inherited from DSIP (PMID: 3628078)
- Bell-shaped dose-response relationships reported in animal studies across multiple experimental settings; doses outside the effective range were ineffective or produced different effects. Inherited from DSIP (PMID: 6548967)
- Epitalon has been identified in illegal pharmaceutical preparations with assumed cancer, anti-aging, and retinitis pigmentosa indications, highlighting risks of unregulated supply and uncertain purity (PMID: 12535022). Inherited from Epitalon (PMID: 12535022)
- One 2026 review classified Epitalon as a 'non-approved peptide' lacking long-term safety data and systematic validation, in contrast to FDA-approved peptide agents (PMID: 35408963). Inherited from Epitalon (PMID: 35408963)
- A 2007 study reported that epitalon injection decreased antioxidant activity in rat serum and cerebral cortex while reducing LPO products, suggesting complex modulation of the redox system that warrants further characterization (PMID: 18239817). Inherited from Epitalon (PMID: 18239817)
- In vitro data suggest Epitalon can extend telomere length in cancer cell lines (via ALT activation), raising a theoretical question about effects in oncological contexts that requires further study (PMID: 40908429). Inherited from Epitalon (PMID: 40908429)
Contraindications
- No explicit contraindications are stated in the reviewed abstracts. The reviewed literature does not identify specific clinical contraindications for DSIP administration. Inherited from DSIP (PMID: 16539679)
- No explicit contraindications are stated in the reviewed abstracts. The reviewed literature does not identify any population for whom Epitalon is formally contraindicated. Inherited from Epitalon (PMID: 40141333)
- DSIP + Epitalon has not been evaluated as a combination in any clinical trial. The lack of combination-specific contraindications reflects that absence of study, not established safety. No combination study cited in either component file